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Background.Extensiveevidence,arisingfrommodelsofendothelialnitricoxidesynthasegene(NOS3)-knockoutmicesupportsthe
role of endothelial malfunction in the pathogenesis of the metabolic syndrome (MS). Aims. The aim of this study was to evaluate
the role of −786T/C polymorphism in the etiology of MS and assess previously reported interaction with cigarette smoking.
Methods. Based on International Diabetes Federation 2005 criteria, we recruited randomly 152 subjects with MS and 75 subjects
without MS. Results. Allelic and genotype frequencies did not diﬀer signiﬁcantly between both groups. Total cholesterol level
(CHOLT) and intima-media thickness of carotid arteries were signiﬁcantly higher in −786CC homozygotes, in comparison with
−786TC and −786TT patients. Regarding current smoking status, −786C allele was associated with higher CHOLT than −786T
allele. Conclusion. Our study indicates the putative role of −786T/C polymorphism in the development of hypercholesterolemia,
in patients with MS, which might be enhanced by cigarette smoking.
1.Introduction
The metabolic syndrome (MS) is a clustering entity, char-
acterized by obesity, hypertension, hyperglycemia, dyslipi-
demia, and insulin resistance. Deﬁnitions of MS were
created in order to indicate the patients at increased risk of
cardiovascular complications and type 2 diabetes. Currently
recommended criteria for MS diagnosing were proposed
by National Cholesterol Education Program (NCEP), Adult
Treatment Panel III (ATP III), and International Diabetes
Federation 2005 (IDF 2005).
Atherosclerotic lesions may be the complication of
MS, arising from endothelial dysfunction and induced by
decreased nitric oxide (NO) production. NO is synthesized
by nitric oxide synthase (eNOS), encoded by NOS3
gene, and displays anti-inﬂammatory, vasodilatory, and
antiproliferative eﬀects [1]. Recent studies also demonstrate
that NOS3-knockout mice develop dyslipidemia, insulin
resistance, decreased insulin-dependent glucose uptake in
skeletal muscles and adipose tissue, and hypertension,
mimicking the phenotype of MS [2–5]. In humans NOS3
gene is located at 7q35-36 and possesses a few polymor-
phic variants. Several reports indicate the potential asso-
ciation between NOS3 gene polymorphisms and MS
[6–8]. Functional polymorphism in the promoter region
(−786T/C) may alter NOS3 gene expression [9, 10]a n dl e a d
to decreased biosynthesis of NO [11]. Although the impact
of −786T/C polymorphism seems to be well established with
regard to several cardiovascular end points, its exact role in
the etiology of MS still remains unclear.
Besides genetic risk factors, atherosclerotic vessel dam-
age may occur due to modiﬁable, environmental insults.
Moreover, a growing body of evidence suggests the role of
gene × environment interactions (G × E) in the etiology
of multifactorial diseases including MS, type 2 diabetes,
and atherosclerosis [12]. Following this notion, cigarette2 International Journal of Endocrinology
smoking may directly reduce eNOS activity and enhance the
endothelial malfunction. However, this alteration probably
depends upon NOS3 genotype [13].
The aim of this study was to evaluate the association
between −786T/C polymorphism and MS, and to assess the
putative G × E interaction with cigarette smoking.
2.MaterialsandMethods
2.1. Subjects. We recruited randomly 227 males without any
previous treatment of dyslipidemia, diabetes, or cardiovas-
cular diseases. To avoid the potential hormonal inﬂuences
and assess the notion that gender may be the risk factor for
vascular incidents, we limited our study to male individuals.
All subjects were Caucasians, worked in the copper smelter,
and came from the same geographic area. Written informed
consent was obtained from all volunteers after the approval
of local Ethics Committee.
Anthropometric measurements were carried out by
trained medical staﬀ and included weight, height, waist,
and hip circumference. On the basis of anthropometric
measurements, waist-to-hip ratio (WHR) and body mass
index (BMI) were calculated. Hypertension was diagnosed
based on blood pressure measurements in a quiet room
after lying down for 15 minutes, which were performed
at least twice during two or three diﬀerent appointments.
Diabetes type 2 or impaired fasting glucose were diagnosed
using WHO criteria. Triglycerides (TG), total cholesterol
(CHOLT), low-density lipoproteins (LDL) and high-density
lipoproteins (HDL) levels were estimated according to
standard protocols. The compound panel of biochemical
measurements was performed in all subjects from both
groups and included coagulation parameters (international
normalized ratio, prothrombin index, and ﬁbrinogen con-
centration), hormones concentrations (thyrotropin, testos-
terone, insulin), C-reactive protein (CRP), uric acid (UA),
and leptin and adiponectin concentrations.
Subjects, who fulﬁlled IDF 2005 criteria for MS, were
recruited into the study group (152 males) and others, with-
out clinical and biochemical features of MS were enrolled
into the control group (75 males).
2.2. DNA Extraction and Genotype Analysis. Genetic anal-
ysis was performed according to the PCR-RFLP protocol,
described by Imamura et al. [14] with the following oligonu-
cleotide primers: 5 -CAT TCT GGG AAC TGT-3  as a
forward sequence and 5 -GTC AGC AGA GAG ACT-3  as a
reversesequence.PCR producthadbeendigestedusingMspI
restriction endonuclease and visualized on 2.5% agarose gel.
2.3. Statistics. Statistical analysis has been performed using
STATISTICA v 9.0 software. Chi-square test has been used
for the evaluation of genetic linkage between −786T/C poly-
morphism and MS. The mean values of clinical parameters
with regard to −786T/C polymorphism have been analyzed
in the Kruskal-Wallis test. Baseline characteristics and the
inﬂuence of cigarette smoking on CHOLT and IMT have
been assessed using the Mann-Whitney U test.
3. Results
Characteristics of study and control group are shown in
Table 1. Genotype and allelic frequencies are presented in
Table 2.T h ed i ﬀerence in −786T/C polymorphism distri-
bution between MS patients and healthy subjects was not
signiﬁcant.
Analysis of mean clinical parameters with regard to
−786T/C polymorphism in study group revealed signiﬁcant
results (Table 3). The diﬀerence in CHOLT between MS
subjects with distinct −786T/C genotypes was statistically
signiﬁcant (−786TT:5.44mmol/L, −786TC:5.47mmol/L,
and −786CC:5.78mmol/L; P = 0.04). Similarly, both
left and right IMT were signiﬁcantly lower in −786TT
homozygotes, in comparison with −786TC and −786CC
patients (for left IMT:0.56cm, 0.57cm, and 0.65cm resp.,
P = 0.04 and for right IMT: 0.54cm, 0.58cm, and 0.65cm
resp., P = 0.02).
The interaction between cigarette smoking and studied
polymorphism was assessed in both groups simultaneously
and revealed signiﬁcant results regarding only CHOLT
(Table 4). The prevalence of current cigarette smoking was
59.2% (90 subjects) in study group and 62.6% (47 subjects)
in control group. CHOLT was signiﬁcantly higher (P =
0.03)in −786TCsmokers(5.74mmol/L)incomparisonwith
−786TC nonsmokers (5.3mmol/L). Higher CHOLT (P =
0.01) was also found in −786CC smokers (5.66mmo/L)
than in −786CC nonsmokers (4,85mmol/L). The diﬀerence
in CHOLT between −786TT smokers and −786TT non-
smokers was not statistically signiﬁcant (5.28mmol/L versus
5.08mmol/L, P = 0.47). Regarding allele carrier status,
−786T allele was associated with signiﬁcantly lower (P =
0.003) CHOLT with respect to −786C allele (5.23mmol/L
versus 5.73mmol/L). It is noteworthy that the mean values
of CHOLT did not diﬀer signiﬁcantly between subjects with
distinctgenotypeseitherinsmokersornonsmokers(datanot
shown).
4. Discussion
Our study did not reveal signiﬁcant association of −786T/C
polymorphism with MS. The subthreshold results may
arise from the study design limitations, originating from
the sample size. However, interesting results were obtained
concerning clinical parameters of MS. We conﬁrmed the
putative impact of −786T/C polymorphism on atheroscle-
rotic lesions by measuring IMT in carotid arteries. These
ﬁndings are consistent with previously published data, based
on various imaging indices of atherosclerosis in MS patients
including aortic and peripheral wave velocity [15] or ankle-
brachial index [16]. According to previously published
data, derived from transcriptional studies, it is unexplained
clearly whether −786T/C polymorphism may decrease the
expression of NOS3 gene and lead to reduction in NO
release [9, 17, 18]. Miyamoto et al. [19] have found the
potential mechanism underlying this phenomenon. They
have observed that only −786C variant is targeted by
replicationproteinA1,whichisasingle-strandDNA-bindingInternational Journal of Endocrinology 3
Table 1: Baseline characteristics of study group and control group.
Parameter Study group Control group P-value∗
Age 46,35 ± 6,64 43,22 ± 5,84 0,001
BMI (kg/m2) 30,49 ± 2,91 24,46 ± 2,08 <0,001
Fatty tissue percentage (%) 28,81 ± 5,72 18,53 ± 4,37 <0,001
Waist circumference (cm) 102,09 ± 7,81 86,79 ± 4,80 <0,001
Hip circumference (cm) 106,75 ± 5,75 98,8 ± 3,51 <0,001
WHR 0,96 ± 0,04 0,88 ± 0,03 <0,001
CHOLT (mmol/L) 5,64 ± 0,93 5,01 ± 0,79 <0,001
LDL (mmol/L) 3,44 ± 0,89 2,84 ± 0,72 <0,001
HDL (mmol/L) 1,31 ± 0,29 1,64 ± 0,42 <0,001
TG (mmol/L) 2,30 ± 1,32 1,18 ± 0,45 <0,001
Uric acid (μmol/L) 368,08 ± 67,13 306,48 ± 61,91 <0,001
CRP (mg/L) 2,89 ± 2,96 1,08 ± 0,92 <0,001
Leptine (ng/mL) 9,59 ± 5,59 4,61 ± 2,04 <0,001
Adiponectine (μg/mL) 6,95 ± 3,50 8,94 ± 3,16 0,002
Left IMT (cm) 0,59 ± 0,15 0,51 ± 0,09 <0,001
Right IMT (cm) 0,59 ± 0,17 0,50 ± 0,08 <0,001
HOMA-IR 3,45 ± 2,21 1,37 ± 0,69 <0,001
QUICKI 0,68 ± 0,41 0,78 ± 0,50 0,18
Results expressed as mean values ± SD. Abbreviations: BMI: body mass index, WHR: waist-to-hip ratio, CHOLT: total cholesterol level, LDL: low density
lipoproteins, HDL: high density lipoproteins, TG: trigllcerides, CRP: C-reactive protein, IMT: intima-media thickness of carotid arteries, HOMA-IR:
Homeostasis Model of Assessment-Insulin Resistance, QUICKI: Quantitative Insulin-Sensitivity Check Index.
∗P-value refers to the Mann-Whitney U test.
Table 2: Genotype and allelic frequency in study group and control group.
Study group Control group OR 95% CI P-value∗
N = 152 N = 75
−786TT
−786TC
−786CC
41 (27%)
89 (58,5%)
22 (14,5%)
25 (33,3%)
41 (54,7%)
9 (12%)
referent
1,17
1,24
0,65–2,04
0,53–2,93
0,61
0,59
−786T 171 (56,25%) 91 (60,67%) referent
−786C 133 (43,75%) 59 (39,33%) 1,19 0,79–1,80 0,37
∗P-value calculated in χ2 test.
transcription factor repressing transcription of NOS3 in
vitro.
The novel ﬁnding, resulting from our study, concerns the
inﬂuence of −786T/C on CHOLT, which was signiﬁcantly
higher in −786CC homozygotes, in comparison with other
genotypes. Emerging data indicate that NOS3-knockout
mice display hypercholesterolemia among other clinical
traits of MS [5, 20]. Although the direct connection between
NO activity and lipid metabolism remains unclear, we
hypothesize that the impact of −786T/C polymorphism in
NOS3 gene on clinical features of MS including cholesterol
metabolism might be less severe than the knockout of the
whole gene. Moreover, the genetic etiology of MS originates
from interactions between a plethora of modest eﬀect loci,
which impair diﬀerent clinical parameters of this clustering
entity. Hence, the only clinical outcome from this study
concerns alterations in CHOLT and IMT.
Furthermore, we evaluated the possible G × E interac-
tions by assessing the synergism between cigarette smoking
and −786T/C polymorphism. According to our results, the
inﬂuence of −786T/C polymorphism might be enhanced
by tobacco smoke ingredients. Statistical analysis revealed
signiﬁcant correlations between CHOLT and −786T/C poly-
morphism in conjunction with current smoking status. The
interaction between smoking and NOS3 polymorphisms has
been assessed in several studies with regard to coronary
artery disease [21, 22], peripheral arterial disease [16], and
cerebrovascular incidents [23]. Moreover, cigarette smoking
may in itself aﬀect NO release [24, 25]. According to the
current knowledge, exposure to cigarette smoke ingredients
may impair eNOS activity in various mechanisms including
release of reactive oxygen species, which contribute to eNOS
uncoupling [26], targeting NOS3 gene expression [27, 28],
altering phosphorylation of eNOS via interactions with4 International Journal of Endocrinology
Table 3: The comparison of mean values of studied parameters in MS subjects.
Parameter −786TT −786TC −786CC P-value∗ −786T −786C P-value∗∗
Overweight percentage (%)24.21 ± 11.95 24.14 ± 13.34 25.08 ± 14.9 0.75 24.16 ± 13.02 24.44 ± 13.8 0.98
BMI (kg/m2) 30.6 ± 2.97 30.41 ± 2.93 30.63 ± 2.89 0.91 30.45 ± 2.91 30.46 ± 2.93 0.95
Waist circumference (cm) 101.81 ± 7.73 102.36 ± 7.78 102.53 ± 8.16 0.87 101.93 ± 7.71 102.05 ± 7.84 0.95
Hip circumference (cm) 106.05 ± 6.01 107 ± 5.81 107.05 ± 5.14 0.31 106.7 ± 5.87 107.01 ± 5.66 0.69
Fatty tissue percentage (%) 29.15 ± 5.37 28.81 ± 7.11 29.15 ± 5.37 0.87 28.7 ± 5.86 28.82 ± 5.47 0.69
WHR 0.95 ± 0.04 0.96 ± 0.03 0.97 ± 0.06 0.84 0.95 ± 0.04 0.96 ± 0.05 0.71
Prothrombin index (%) 103.02 ± 6.53 100.7 ± 8.48 99.44 ± 8.93 0.35 101.17 ± 8.15 100.3 ± 8.61 0.62
INR 1.25 ± 1.45 0.99 ± 0.08 0.97 ± 0.06 0.31 1.07 ± 0.82 0.99 ± 0.08 0.51
Fibrynogen (g/L) 3.23 ± 0.65 3.41 ± 0.58 3.56 ± 0.48 0.19 3.37 ± 0.59 3.46 ± 0.55 0.46
CHOLT (mmol/L) 5.44 ± 0.85 5.47 ± 0.98 5.78 ± 0.94 0.04 5.67 ± 0.92 5.72 ± 0.95 0.58
LDL (mmol/L) 3.30 ± 0.82 3.34 ± 0.82 3.52 ± 0.94 0.11 3.45 ± 0.91 3.49 ± 0.92 0.64
HDL (mmol/L) 1.32 ± 0.27 1.29 ± 0.36 1.28 ± 0.28 0.6 1.31 ± 0.27 1.32 ± 0.29 0.76
TG (mmol/L) 1.83 ± 0.59 2.19 ± 1.2 2.47 ± 1.47 0.19 2.34 ± 1.36 2.37 ± 1.39 0.78
Uric acid (μmol/L) 361.72 ± 69.2 368.09 ± 64.7 381.73 ± 63.26 0.19 362.99 ± 68.09 368.08 ± 67.78 0.52
CRP (mg/L) 2.75 ± 2.12 2.77 ± 2.64 3.36 ± 2.98 0.86 2.91 ± 3.01 2.95 ± 3.22 0.91
TSH (mU/L) 1.52 ± 1.21 1.53 ± 0.75 1.67 ± 0.88 0.21 1.52 ± 1.08 1.55 ± 1.15 0.92
Testosterone (pg/mL) 4.64 ± 1.51 4.1 ± 1.3 4.05 ± 1.4 0.28 4.08 ± 1.33 4.21 ± 1.36 0.54
Leptin (ng/mL) 9.11 ± 4.51 9.61 ± 6.21 10.39 ± 4.85 0.46 9.45 ± 5.71 9.76 ± 5.95 0.69
Adiponectin (μg/mL) 7.28 ± 4.12 7.23 ± 3.54 6.14 ± 2.95 0.23 7.24 ± 3.65 6.88 ± 3.39 0.68
Right IMT (mm) 0.54 ± 0.11 0.58 ± 0.15 0.65 ± 0.23 0.02 0.57 ± 0.14 0.6 ± 0.18 0.15
Left IMT (mm) 0.56 ± 0.12 0.57 ± 0.13 0.65 ± 0.2 0.04 0.56 ± 0.12 0.59 ± 0.16 0.29
HOMA-IR 3.35 ± 2.27 3.48 ± 1.56 3.63 ± 2.4 0.50 3.37 ± 2.15 3.44 ± 2.31 0.78
QUICKI 0.74 ± 0.5 0.65 ± 0.28 0.55 ± 0.16 0.07 0.71 ± 0.44 0.69 ± 0.45 0.97
Results expressed as mean values ± SD. Abbreviations: BMI: body mass index. WHR: waist-to-hip ratio. INR: International Normalized Ratio. CHOLT: total
cholesterol level. LDL: low density lipoproteins. HDL: high density lipoproteins. TG: triglycerides. CRP: C-reactive protein. TSH: thyrotropin. IMT: intima-
media thickness of carotid arteries. HOMA-IR: Homeostasis Model of Assessment-Insulin Resistance. QUICKI: Quantitative Insulin-Sensitivity Check Index.
∗P-value refers to the Kruskal-Wallis test and ∗∗P-value refers to the Mann-Whitney U test.
Table 4: The inﬂuence of cigarette smoking on total cholesterol level (CHOLT) and intima-media thickness (IMT) in men with particular
genotype or allele of −786T/C polymorphism.
Genotype/allele Parameter Smokers Non-smokers P-value∗
−786CC
CHOLT (mmol/L)
Left IMT (cm)
Right IMT (cm)
5.66
0.55
0.52
4.85
0.53
0.5
0.01
0.81
0.96
−786TC
CHOLT (mmol/L)
Left IMT (cm)
Right IMT
5.74
0.55
0.56
5.3
0.54
0.55
0.03
0.47
0.94
−786TT
CHOLT (mmol/L)
Left IMT (cm)
Right IMT (cm)
5.28
0.61
0.6
5.08
0.59
0.58
0.47
0.57
0.5
−786C (CC + TC)
CHOLT (mmol/L)
Left IMT (cm)
Right IMT (cm)
5.73
0.55
0.56
5.27
0.54
0.54
0.003
0.41
0.84
−786T (TT + TC)
CHOLT (mmol/L)
Left IMT (cm)
Right IMT (cm)
5.57
0.56
0.57
5.28
0.55
0.56
0.06
0.61
0.69
Results expressed as mean values. Abbreviations: CHOLT: total cholesterol level. IMT: intima-media thickness of carotid arteries.
∗P-value calculated in the Mann-Whitney U test.International Journal of Endocrinology 5
protein kinase C [29], as well as accelerating catabolism of
tetrahydrobiopterin, which is the eNOS-cofactor [30]. The
limitation of this study is that we did not assess the putative
dose-dependent eﬀect of active smoking. However, previous
studies suggest that heavy and light smokers may display
similar deleterious eﬀects on NO biosynthesis [31].
5. Conclusions
Ourresultssupporttheinﬂuenceof −786T/Cpolymorphism
on clinical features of MS. Moreover, this study sheds new
light on the role of NO in the development of hyper-
cholesterolemia. Studied polymorphism may alter NOS3
gene expression and contribute to lipid dysmetabolism.
Thus, observed impact of −786T/C polymorphism on
atherosclerotic indices not only might constitute the direct
eﬀect of endothelial damage but could also appear due to
elevated CHOLT. On the other hand, −786C allele may
enhance deleterious eﬀects of cigarette smoking. However,
the exact mechanism of this G × E interaction requires
further investigation.
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